[1]
Shibanuma, M.; Mashimo, J.; Mita, A.; Kuroki, T.; Nose, K. Cloning from a mouse osteoblastic cell line of a set of transforming-growth-factor-beta 1-regulated genes, one of which seems to encode a follistatin-related polypeptide. Eur. J. Biochem., 1993, 217(1), 13-19.
[2]
Hambrock, H.O.; Kaufmann, B.; Müller, S.; Hanisch, F.G.; Nose, K.; Paulsson, M.; Maurer, P.; Hartmann, U. Structural characterization of TSC-36/Flik: Analysis of two charge isoforms. J. Biol. Chem., 2004, 279(1), 11727-11735.
[3]
Widera, C.; Horn-Wichmann, R.; Kempf, T.; Bethmann, K.; Fiedler, B.; Sharma, S.; Lichtinghagen, R.; Leitolf, H.; Ivandic, B.; Katus, H.A.; Giannitsis, E.; Wollert, K.C. Circulating concentrations of follistatin-like 1 in healthy individuals and patients with acute coronary syndrome as assessed by an immunoluminometric sandwich assay. Clin. Chem., 2009, 55(1), 1794-1800.
[4]
Tanaka, M.; Ozaki, S.; Osakada, F.; Mori, K.; Okubo, M.; Nakao, K. Cloning of follistatin-related protein as a novel autoantigen in systemic rheumatic diseases. Int. Immunol., 1998, 10(1), 1305-1314.
[5]
Zwijsen, A.; Blockx, H.; Van Arnhem, W.; Willems, J.; Fransen, L.; Devos, K.; Raymackers, J.; Van de Voorde, A.; Slegers, H. Characterization of a rat C6 glioma-secreted follistatin-related protein (FRP). Cloning and sequence of the human homologue. Eur. J. Biochem., 1994, 225(1), 937-946.
[6]
Miyamae, T.; Marinov, A.D.; Sowders, D.; Wilson, D.C.; Devlin, J.; Boudreau, R.; Robbins, P.; Hirsch, R. Follistatin-like protein-1 is a novel proinflammatory molecule. J. Immunol., 2006, 177(7), 4758-4762.
[7]
Oshima, Y.; Ouchi, N.; Sato, K.; Izumiya, Y.; Pimentel, D.R.; Walsh, K. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation, 2008, 117(24), 3099-3108.
[8]
Gorgens, S.W.; Raschke, S.; Holven, K.B.; Jensen, J.; Eckardt, K.; Eckel, J. Regulation of follistatin-like protein 1 expression and secretion in primary human skeletal muscle cells. Arch. Physiol. Biochem., 2013, 119(2), 75-80.
[9]
Lara-Pezzi, E.; Felkin, L.E.; Birks, E.J.; Sarathchandra, P.; Panse, K.D.; George, R.; Hall, J.L.; Yacoub, M.H.; Rosenthal, N.; Barton, P.J. Expression of follistatin-related genes is altered in heart failure. Endocrinology, 2008, 149(11), 5822-5827.
[10]
Adams, D.; Larman, B.; Oxburgh, L. Developmental expression of mouse Follistatin-like 1 (Fstl1): Dynamic regulation during organogenesis of the kidney and lung. Gene Expr. Patt, 2007, 7(4), 491-500.
[11]
Sumitomo, K.; Kurisaki, A.; Yamakawa, N.; Tsuchida, K.; Shimizu, E.; Sone, S.; Sugino, H. Expression of a TGF-beta1 inducible gene, TSC-36, causes growth inhibition in human lung cancer cell lines. Cancer Lett., 2000, 155(1), 37-46.
[12]
Sylva, M.; Moorman, A.F.; van den Hoff, M.J. Follistatin-like 1 in vertebrate development. Birth Defects Res. C Embryo Today, 2013, 99(1), 61-69.
[13]
Ambrosy, A.P.; Fonarow, G.C.; Butler, J.; Chioncel, O.; Greene, S.J.; Vaduganathan, M.; Nodari, S.; Lam, C.S.P.; Sato, N.; Shah, A.N.; Gheorghiade, M. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. J. Am. Coll. Cardiol., 2014, 63(1), 1123-1133.
[14]
Taylor, C.J.; Ryan, R.; Nichols, L.; Gale, N.; Hobbs, F.R.; Marshall, T. Survival following a diagnosis of heart failure in primary care. Fam. Pract., 2017, 34(2), 161-168.
[15]
Fisher, S.A.; Zhang, H.; Doree, C.; Mathur, A.; Martin-Rendon, E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst. Rev., 2015.CD006536
[16]
Van den Akker, F.; Feyen, D.A.; van den Hoogen, P.; van Laake, L.W.; van Eeuwijk, E.C.; Hoefer, I.; Pasterkamp, G.; Chamuleau, S.A.; Grundeman, P.F.; Doevendans, P.A.; Sluijter, J.P. Intramyocardial stem cell injection: Go(ne) with the flow. Eur. Heart J., 2017, 38(3), 184-186.
[17]
Madonna, R.; Van Laake, L.W.; Davidson, S.M.; Engel, F.B.; Hausenloy, D.J.; Lecour, S.; Leor, J.; Perrino, C.; Schulz, R.; Ytrehus, K.; Landmesser, U.; Mummery, C.L.; Janssens, S.; Willerson, J.; Eschenhagen, T.; Ferdinandy, P.; Sluijter, J.P. Position paper of the european society of cardiology working group cellular biology of the heart: Cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur. Heart J., 2016, 37(23), 1789-1798.
[18]
Fernández-Avilés, F.; Sanz-Ruiz, R.; Climent, A.M.; Badimon, L.; Bolli, R.; Charron, D.; Fuster, V.; Janssens, S.; Kastrup, J.; Kim, H.S.; Lüscher, T.F.; Martin, J.F.; Menasché, P.; Simari, R.D.; Stone, G.W.; Terzic, A.; Willerson, J.T.; Wu, J.C. Global position paper on cardiovascular regenerative medicine. Eur. Heart J., 2017, 38(33), 2532-2546.
[19]
Sluijter, J.P.G.; Davidson, S.M.; Boulanger, C.M.; Buzás, E.I.; de Kleijn, D.P.V.; Engel, F.B.; Giricz, Z.; Hausenloy, D.J.; Kishore, R.; Lecour, S.; Leor, J.; Madonna, R.; Perrino, C.; Prunier, F.; Sahoo, S.; Schiffelers, R.M.; Schulz, R.; Van Laake, L.W.; Ytrehus, K.; Ferdinandy, P. Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position paper from the working group on cellular biology of the heart of the European society of cardiology. Cardiovasc. Res., 2018, 114(1), 19-34.
[20]
Shimano, M.; Ouchi, N.; Walsh, K. Cardiokines: Recent progress in elucidating the cardiac secretome. Circulation, 2012, 126(1), e327-e332.
[21]
Deddens, J.C.; Vrijsen, K.R.; Girao, H.; Doevendans, P.A.; Sluijter, J.P. Cardiac-released extracellular vesicles can activate endothelial cells. Ann. Transl. Med., 2017, 5(1), 64.
[22]
Doroudgar, S.; Glembotski, C.C. The cardiokine story unfolds: ischemic stress-induced protein secretion in the heart. Trends Mol. Med., 2011, 17(4), 207-214.
[23]
Jahng, J.W.; Song, E.; Sweeney, G. Crosstalk between the heart and peripheral organs in heart failure. Exp. Mol. Med., 2016, 48(1)e217
[24]
Walsh, K. Adipokines, myokines and cardiovascular disease. Circ. J., 2009, 73(1), 13-18.
[25]
Chiba, A.; Watanabe-Takano, H.; Miyazaki, T.; Mochizuki, N. Cardiomyokines from the heart. Cell. Mol. Life Sci., 2018, 75(1), 1349-1362.
[26]
Mattiotti, A.; Prakash, S.; Barnett, P.; van den Hoff, M.J.B. Follistatin-like 1 in development and human diseases. Cell. Mol. Life Sci., 2018, 75(1), 2339-2354.
[27]
Shimano, M.; Ouchi, N.; Nakamura, K.; van Wijk, B.; Ohashi, K.; Asaumi, Y.; Higuchi, A.; Pimentel, D.R.; Sam, F.; Murohara, T.; van den Hoff, M.J.; Walsh, K. Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. Proc. Natl. Acad. Sci. USA, 2011, 108(2), E899-E906.
[28]
Liu, S.; Wang, L.; Wang, W.; Lin, J.; Han, J.; Sun, H.; Guo, H.; Sun, R.; Wu, Q. TSC-36/FRP inhibits vascular smooth muscle cell proliferation and migration. Exp. Mol. Pathol., 2006, 80(1), 132-140.
[29]
Ouchi, N.; Asaumi, Y.; Ohashi, K.; Higuchi, A.; Sono-Romanelli, S.; Oshima, Y.; Walsh, K. DIP2A functions as a FSTL1 receptor. J. Biol. Chem., 2010, 285(1), 7127-7134.
[30]
Ogura, Y.; Ouchi, N.; Ohashi, K.; Shibata, R.; Kataoka, Y.; Kambara, T.; Kito, T.; Maruyama, S.; Yuasa, D.; Matsuo, K.; Enomoto, T.; Uemura, Y.; Miyabe, M.; Ishii, M.; Yamamoto, T.; Shimizu, Y.; Walsh, K.; Murohara, T. Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation, 2012, 126(14), 1728-1738.
[31]
Xi, Y.; Gong, D.W.; Tian, Z. FSTL1 as a potential mediator of Exercise-Induced cardioprotection in Post-Myocardial infarction rats. Sci. Rep., 2016, 6(1), 32424.
[32]
Beauloye, C.; Bertrand, L.; Horman, S.; Hue, L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc. Res., 2011, 90(2), 224-233.
[33]
Xiao, Y.; Zhang, Y.; Chen, Y.; Li, J.; Zhang, Z.; Sun, Y.; Shen, H.; Zhao, Z.; Huang, Z.; Zhang, W.; Chen, W.; Shen, Z. Inhibition of MicroRNA-9-5p Protects against cardiac remodeling following myocardial infarction in mice. Hum. Gene Ther., 2018.
[34]
Wei, K.; Serpooshan, V.; Hurtado, C.; Diez-Cuñado, M.; Zhao, M.; Maruyama, S.; Zhu, W.; Fajardo, G.; Noseda, M.; Nakamura, K.; Tian, X.; Liu, Q.; Wang, A.; Matsuura, Y.; Bushway, P.; Cai, W.; Savchenko, A.; Mahmoudi, M.; Schneider, M.D.; van den Hoff, M.J.; Butte, M.J.; Yang, P.C.; Walsh, K.; Zhou, B.; Bernstein, D.; Mercola, M.; Ruiz-Lozano, P. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. Nature, 2015, 525(1), 479-485.
[35]
van Rooij, E. Cardiac repair after myocardial infarction. N. Engl. J. Med., 2016, 374(1), 85-87.
[36]
Bergmann, O.; Zdunek, S.; Felker, A.; Salehpour, M.; Alkass, K.; Bernard, S.; Sjostrom, S.L.; Szewczykowska, M.; Jackowska, T.; Dos Remedios, C.; Malm, T.; Andrä, M.; Jashari, R.; Nyengaard, J.R.; Possnert, G.; Jovinge, S.; Druid, H.; Frisén, J. Dynamics of Cell Generation and Turnover in the Human Heart. Cell, 2015, 161(7), 1566-1575.
[37]
Buggisch, M.; Ateghang, B.; Ruhe, C.; Strobel, C.; Lange, S.; Wartenberg, M.; Sauer, H. Stimulation of ES-cell-derived cardiomyogenesis and neonatal cardiac cell proliferation by reactive oxygen species and NADPH oxidase. J. Cell Sci., 2007, 120(Pt 5), 885-894.
[38]
D’Uva, G.; Aharonov, A.; Lauriola, M.; Kain, D.; Yahalom-Ronen, Y.; Carvalho, S.; Weisinger, K.; Bassat, E.; Rajchman, D.; Yifa, O.; Lysenko, M.; Konfino, T.; Hegesh, J.; Brenner, O.; Neeman, M.; Yarden, Y.; Leor, J.; Sarig, R.; Harvey, R.P.; Tzahor, E. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat. Cell Biol., 2015, 17(5), 627-638.
[39]
Heallen, T.; Zhang, M.; Wang, J.; Bonilla-Claudio, M.; Klysik, E.; Johnson, R.L.; Martin, J.F. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science, 2011, 332(6028), 458-461.
[40]
Widera, C.; Giannitsis, E.; Kempf, T.; Korf-Klingebiel, M.; Fiedler, B.; Sharma, S.; Katus, H.A.; Asaumi, Y.; Shimano, M.; Walsh, K.; Wollert, K.C. Identification of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome. Clin. Chem., 2012, 58(8), 1233-1241.
[41]
Kretzschmar, K.; Post, Y.; Bannier-Hélaouët, M.; Mattiotti, A.; Drost, J.; Basak, O.; Li, V.S.W.; van den Born, M.; Gunst, Q.D.; Versteeg, D.; Kooijman, L.; van der Elst, S.; van Es, J.H.; van Rooij, E.; van den Hoff, M.J.B.; Clevers, H. Profiling proliferative cells and their progeny in damaged murine hearts. PNAS, 2018, 115(52), E12245-E12254.
[42]
Ouchi, N.; Oshima, Y.; Ohashi, K.; Higuchi, A.; Ikegami, C.; Izumiya, Y.; Walsh, K. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J. Biol. Chem., 2008, 283(47), 32802-32811.
[43]
Miyabe, M.; Ohashi, K.; Shibata, R.; Uemura, Y.; Ogura, Y.; Yuasa, D.; Kambara, T.; Kataoka, Y.; Yamamoto, T.; Matsuo, K.; Joki, Y.; Enomoto, T.; Hayakawa, S.; Hiramatsu-Ito, M.; Ito, M.; Van Den Hoff, M.J.; Walsh, K.; Murohara, T.; Ouchi, N. Muscle-derived follistatin-like 1 functions to reduce neointimal formation after vascular injury. Cardiovasc. Res., 2014, 103(1), 111-120.
[44]
Wollert, K.C.; Kempf, T.; Peter, T.; Olofsson, S.; James, S.; Johnston, N.; Lindahl, B.; Horn-Wichmann, R.; Brabant, G.; Simoons, M.L.; Armstrong, P.W.; Califf, R.M.; Drexler, H.; Wallentin, L. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation, 2007, 115(8), 962-971.
[45]
El-Armouche, A.; Ouchi, N.; Tanaka, K.; Doros, G.; Wittköpper, K.; Schulze, T.; Eschenhagen, T.; Walsh, K.; Sam, F. Follistatin-like 1 in chronic systolic heart failure: A marker of left ventricular remodeling. Circ Heart Fail, 2011, 4(5), 621-627.
[46]
Tanaka, K.; María, V-M.; Richard, M.; Wilson, B.S.; Eric, E. Essick, Conor, T.; Fowler, B.S.; Kazuto, N.; Maurice, van den Hoff.; Noriyuki, O.; Flora, S. Follistatin like 1 regulates hypertrophy in heart failure with preserved ejection fraction. JACC Basic Transl. Sci., 2016, 1(4), 207-221.
[47]
Namdari, M.; Negahdari, B.; Cheraghi, M.; Aiyelabegan, H.T.; Eatmadi, A. Cardiac failure detection in 30 minutes: New approach based on gold nanoparticles. J. Microencapsul., 2017, 34(2), 132-139.
[48]
Seki, M.; Powers, J.C.; Maruyama, S.; Zuriaga, M.A.; Wu, C.L.; Kurishima, C.; Kim, L.; Johnson, J.; Poidomani, A.; Wang, T.; Muñoz, E.; Rajan, S.; Park, J.Y.; Walsh, K.; Recchia, F.A. Acute and chronic increases of circulating fstl1 normalize energy substrate metabolism in pacing-induced heart failure. Circ Heart Fail, 2018, 11(11)e004486
[49]
Zhang, W.; Wang, W.; Liu, J.; Li, J.; Wang, J.; Zhang, Y.; Zhang, Z.; Liu, Y.; Jin, Y.; Li, J.; Cao, J.; Wang, C.; Ning, W.; Wang, J. Follistatin-like 1 protects against hypoxia-induced pulmonary hypertension in mice. Sci. Rep., 2017, 7(1), 45820.
[50]
Tania, N.P.; Maarsingh, H.T.; Bos, I.S.; Mattiotti, A.; Prakash, S.; Timens, W.; Gunst, Q.D.; Jimenez-Borreguero, L.J.; Schmidt, M.; van den Hoff, M.J.B.; Gosens, R. Endothelial follistatin-like-1 regulates the postnatal development of the pulmonary vasculature by modulating BMP/Smad signaling. Pulm. Circ., 2017, 7(1), 219-231.
[51]
Prakash, S.; Borreguero, L.J.J.; Sylva, M.; Flores Ruiz, L.; Rezai, F.; Gunst, Q.D.; de la Pompa, J.L.; Ruijter, J.M.; van den Hoff, M.J.B. Deletion of Fstl1 (Follistatin-Like 1) From the endocardial/endothelial lineage causes mitral valve disease. Arterioscler. Thromb. Vasc. Biol., 2017, 37(9), e116-e130.
[52]
Ruparelia, N.; Chai, J.T.; Fisher, E.A.; Choudhury, R.P. Inflammatory processes in cardiovascular disease: A route to targeted therapies. Nat. Rev. Cardiol., 2017, 14(3), 314.
[53]
Mullenix, P.S.; Andersen, C.A., and ; Starnes, B.W. Atherosclerosis as inflammation. Ann. Vasc. Surg., 2005, 19(1), 130-138.
[54]
Maekawa, N.; Wada, H.; Kanda, T.; Niwa, T.; Yamada, Y.; Saito, K.; Fujiwara, H.; Sekikawa, K.; Seishima, M. Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-alpha. J. Am. Coll. Cardiol., 2002, 39(7), 1229-1235.
[55]
Jiang, B.; Liao, R. The paradoxical role of inflammation in cardiac repair and regeneration. J. Cardiovasc. Transl. Res., 2010, 3(4), 410-416.
[56]
Aurora, A.B.; Porrello, E.R.; Tan, W.; Mahmoud, A.I.; Hill, J.A.; Bassel-Duby, R.; Sadek, H.A.; Olson, E.N. Macrophages are required for neonatal heart regeneration. J. Clin. Invest., 2014, 124(3), 1382-1392.
[57]
Xia, Y.; Lee, K.; Li, N.; Corbett, D.; Mendoza, L.; Frangogiannis, N.G. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem. Cell Biol., 2009, 131(4), 471-481.
[58]
Humbert, M.; Monti, G.; Brenot, F.; Sitbon, O.; Portier, A.; Grangeot-Keros, L.; Duroux, P.; Galanaud, P.; Simonneau, G.; Emilie, D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med., 1995, 151(5), 1628-1631.
[59]
Li, D.; Wang, Y.; Xu, N.; Wei, Q.; Wu, M.; Li, X.; Zheng, P.; Sun, S.; Jin, Y.; Zhang, G.; Liao, R.; Zhang, P. Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritis. Arthrit Res. Ther., 2011, 13(1), R17.
[60]
Wilson, D.C.; Marinov, A.D.; Blair, H.C.; Bushnell, D.S.; Thompson, S.D.; Chaly, Y.; Hirsch, R. Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum., 2010, 62(8), 2510-2516.
[61]
Miller, M.; Beppu, A.; Rosenthal, P.; Pham, A.; Das, S.; Karta, M.; Song, D.J.; Vuong, C.; Doherty, T.; Croft, M.; Zuraw, B.; Zhang, X.; Gao, X.; Aceves, S.; Chouiali, F.; Hamid, Q.; Broide, D.H. Fstl1 promotes asthmatic airway remodeling by inducing oncostatin. M. J. Immunol., 2015, 195(8), 3546-3556.
[62]
Gorelik, M.; Wilson, D.C.; Cloonan, Y.K.; Shulman, S.T.; Hirsch, R. Plasma follistatin-like protein 1 is elevated in Kawasaki disease and may predict coronary artery aneurysm formation. J. Pediatr., 2012, 161(1), 116-119.
[63]
Fan, N.; Sun, H.; Wang, Y.; Wang, Y.; Zhang, L.; Xia, Z.; Peng, L.; Hou, Y.; Shen, W.; Liu, R.; Yin, J.; Peng, Y. Follistatin-like 1: A potential mediator of inflammation in obesity. Mediat Inflamm., 2013, 2013(1)752519
[64]
Clutter, S.D.; Wilson, D.C.; Marinov, A.D.; Hirsch, R. Follistatin-like protein 1 promotes arthritis by up-regulating IFN-gamma. J. Immunol., 2009, 182(1), 234-239.
[65]
Chaly, Y.; Marinov, A.D.; Oxburgh, L.; Bushnell, D.S.; Hirsch, R. FSTL1 promotes arthritis in mice by enhancing inflammatory cytokine/chemokine expression. Arthrit Rheum., 2012, 64(4), 1082-1088.
[66]
Ni, S.; Miao, K.; Zhou, X.; Xu, N.; Li, C.; Zhu, R.; Sun, R.; Wang, Y. The involvement of follistatin-like protein 1 in osteoarthritis by elevating NF-kappaB-mediated inflammatory cytokines and enhancing fibroblast like synoviocyte proliferation. Arthrit Res. Ther., 2015, 17(1), 91.
[67]
Chaly, Y.; Fu, Y.; Marinov, A.; Hostager, B.; Yan, W.; Campfield, B.; Kellum, J.A.; Bushnell, D.; Wang, Y.; Vockley, J.; Hirsch, R. Follistatin-like protein 1 enhances NLRP3 inflammasome-mediated IL-1beta secretion from monocytes and macrophages. Eur. J. Immunol., 2014, 44(5), 1467-1479.
[68]
Kwak, H.B.; Ha, H.; Kim, H.N.; Lee, J.H.; Kim, H.S.; Lee, S.; Kim, H.M.; Kim, J.Y.; Kim, H.H.; Song, Y.W.; Lee, Z.H. Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthrit Rheum., 2008, 58(5), 1332-1342.
[69]
Kawabata, D.; Tanaka, M.; Fujii, T.; Umehara, H.; Fujita, Y.; Yoshifuji, H.; Mimori, T.; Ozaki, S. Ameliorative effects of follistatin-related protein/TSC-36/FSTL1 on joint inflammation in a mouse model of arthritis. Arthritis Rheum., 2004, 50(2), 660-668.
[70]
Conway, J.G. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J. Exp. Med., 1995, 182(2), 449-457.
[71]
Dooley, S.; Herlitzka, I.; Hanselmann, R.; Ermis, A.; Henn, W.; Remberger, K.; Hopf, T.; Welter, C. Constitutive expression of c-fos and c-jun, overexpression of ets-2, and reduced expression of metastasis suppressor gene nm23-H1 in rheumatoid arthritis. Ann. Rheum. Dis., 1996, 55(5), 298-304.
[72]
Shiozawa, S.; Shimizu, K.; Tanaka, K.; Hino, K. Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J. Clin. Invest., 1997, 99(6), 1210-1216.
[73]
Tamura, T.; Udagawa, N.; Takahashi, N.; Miyaura, C.; Tanaka, S.; Yamada, Y.; Koishihara, Y.; Ohsugi, Y.; Kumaki, K.; Taga, T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA, 1993, 90(24), 11924-11948.
[74]
Cheng, K.Y.; Liu, Y.; Han, Y.G.; Li, J.K.; Jia, J.L.; Chen, B.; Yao, Z.X.; Nie, L.; Cheng, L. Follistatin-like protein 1 suppressed pro-inflammatory cytokines expression during neuroinflammation induced by lipopolysaccharide. J. Mol. Histol., 2017, 48(2), 63-72.
[75]
Hayakawa, S.; Ohashi, K.; Shibata, R.; Kataoka, Y.; Miyabe, M.; Enomoto, T.; Joki, Y.; Shimizu, Y.; Kambara, T.; Uemura, Y.; Yuasa, D.; Ogawa, H.; Matsuo, K.; Hiramatsu-Ito, M.; van den Hoff, M.J.; Walsh, K.; Murohara, T.; Ouchi, N. Cardiac myocyte-derived follistatin-like 1 prevents renal injury in a subtotal nephrectomy model. J. Am. Soc. Nephrol., 2015, 26(3), 636-646.
[76]
Murakami, K.; Tanaka, M.; Usui, T.; Kawabata, D.; Shiomi, A.; Iguchi-Hashimoto, M.; Shimizu, M.; Yukawa, N.; Yoshifuji, H.; Nojima, T.; Ohmura, K.; Fujii, T.; Umehara, H.; Mimori, T. Follistatin-related protein/follistatin-like 1 evokes an innate immune response via CD14 and toll-like receptor 4. FEBS Lett., 2012, 586(4), 319-324.
[77]
Guo, J.; Liang, W.; Li, J.; Long, J. Knockdown of FSTL1 inhibits oxLDL-induced inflammation responses through the TLR4/ MyD88/NF-kappaB and MAPK pathway. Biochem. Biophys. Res. Commun., 2016, 478(4), 1528-1533.
[78]
Maruyama, S.; Nakamura, K.; Papanicolaou, K.N.; Sano, S.; Shimizu, I.; Asaumi, Y.; van den Hoff, M.J.; Ouchi, N.; Recchia, F.A.; Walsh, K. Follistatin-like 1 promotes cardiac fibroblast activation and protects the heart from rupture. EMBO Mol. Med., 2016, 8(8), 949-966.
[79]
Magadum, A.; Singh, N.; Kurian, A.A.; Sharkar, M.T.K.; Chepurko, E.; Zangi, L. Ablation of a Single N-Glycosylation Site in Human FSTL 1 Induces Cardiomyocyte Proliferation and Cardiac Regeneration. Mol. Ther. Nucleic Acids, 2018, 13(7), 133-143.
[80]
Amado, L.C.; Saliaris, A.P.; Schuleri, K.H.; St John, M.; Xie, J.S.; Cattaneo, S.; Durand, D.J.; Fitton, T.; Kuang, J.Q.; Stewart, G.; Lehrke, S.; Baumgartner, W.W.; Martin, B.J.; Heldman, A.W.; Hare, J.M. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc. Natl. Acad. Sci. USA, 2005, 102(32), 11474-11479.
[81]
Garbayo, E.; Gavira, J.J.; de Yebenes, M.G.; Pelacho, B.; Abizanda, G.; Lana, H.; Blanco-Prieto, M.J.; Prosper, F. Catheter-based intramyocardial injection of FGF1 or NRG1-loaded MPs improves cardiac function in a preclinical model of ischemia-reperfusion. Sci. Rep., 2016, 6(1), 25932.
[82]
Ota, T.; Patronik, N.A.; Schwartzman, D.; Riviere, C.N.; Zenati, M.A. Minimally invasive epicardial injections using a novel semiautonomous robotic device. Circulation, 2008, 118(14)(Suppl.), S115-S120.
[83]
van Slochteren, F.J.; van Es, R.; Gyöngyösi, M.; van der Spoel, T.I.G.; Koudstaal, S.; Leiner, T.; Doevendans, P.A.; Chamuleau, S.A.J. Three-dimensional fusion of electromechanical mapping and magnetic resonance imaging for real-time navigation of intramyocardial cell injections in a porcine model of chronic myocardial infarction. Intl. J. Cardiovasc. Imaging, 2016, 32(5), 833-843.
[84]
Pape, A.C.; Bakker, M.H.; Tseng, C.C.; Bastings, M.M.; Koudstaal, S.; Agostoni, P.; Chamuleau, S.A.; Dankers, P.Y. An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart. J. Vis. Exp., 2015, 100(1)e52450
[85]
Kwekkeboom, R.F.; Lei, Z.; Doevendans, P.A.; Musters, R.J.; Sluijter, J.P. Targeted delivery of miRNA therapeutics for cardiovascular diseases: Opportunities and challenges. Clin. Sci. (Lond.), 2014, 127(6), 351-365.